Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5, 7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27) ,9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer

Journal of Medicinal Chemistry

Volumn 55, Issue 1, 2012, Pages 169-196

  William, Anthony D ^a   Lee, Angeline C H ^a   Goh, Kee Chuan ^a   Blanchard, Stéphanie ^a   Poulsen, Anders ^a   Teo, Ee Ling ^a   Nagaraj, Harish ^a   Lee, Chai Ping ^a   Wang, Haishan ^a   Williams, Meredith ^a   Sun, Eric T ^a   Hu, Changyong ^a   Jayaraman, Ramesh ^a   Pasha, Mohammed Khalid ^a   Ethirajulu, Kantharaj ^a   Wood, Jeanette M ^a   Dymock, Brian W ^a  

^a S BIO Pte Ltd   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CYCLIN DEPENDENT KINASE; JANUS KINASE 2; MACROCYCLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; CYCLIN-DEPENDENT KINASES; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FMS-LIKE TYROSINE KINASE 3; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; JANUS KINASE 3; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSOMES, LIVER; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 84862908102     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201112g     Document Type: Article

References (41)

1. Cantley, L. C. and Baselga, J. The era of cancer discovery. Cancer Discovery [Online early access]. DOI: 10.1158/2159-8274.CD-11-0049. Published Online: Apr 3, 2011.
2. Bianco, R.; Damiano, V.; Gelardi, T.; Daniele, G.; Ciardiello, F.; Tortora, G. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling Curr. Pharm. Des. 2007, 13, 3358-3367
3. Mayfield, E. Combining targeted cancer therapies: much promise, many hurdles. NCI Cancer Bull. 2011, 8 (No. 10).
4. Rexer, B. N.; Ghosh, R.; Arteaga, C. L. Inhibition of PI3K and MEK: It is all about combinations and biomarkers Clin. Cancer Res. 2009, 15, 4518-4520
5. Flaherty, K. T. Sorafenib: delivering a targeted drug to the right targets Expert Rev. Anticancer Ther. 2007, 7, 617-626
6. Mena, A. C.; Pulido, E. G.; Guillén-Ponce, C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib Anti-Cancer Drugs 2010, 21 (Suppl. 1) S3-11
7. Lai, C.-J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D.-G.; Yin, L.; Samson, M.; Forrester, J.; Zifcak, B.; Xu, G.-X.; DellaRocca, S.; Zhai, H.-X.; Cai, X.; Munger, W. E.; Keegan, M.; Pepicelli, C. V.; Qian, C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2 exerts potent anticancer activity Cancer Res. 2010, 70, 3647-3656
8. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases Trends Pharmacol. Sci. 2002, 23, 417-425
9. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment J. Clin. Oncol. 2006, 24, 1770-1783
10. Cai, D.; Latham, V. M., Jr.; Zhang, X.; Shapiro, G. I. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells Cancer Res. 2006, 66, 9270-9280
11. Jorda, R.; Havlicek, L.; McNae, I. W.; Walkinshaw, M. D.; Voller, J.; Sturc, A.; Navratilova, J.; Kuzma, M.; Mistrik, M.; Bartek, J.; Strnad, M.; Krystof, V. Pyrazolo[4,3- d ]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity J. Med. Chem. 2011, 54, 2980-2993
12. Wyatt, P. G.; Woodhead, A. J.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Davis, D. J.; Devine, L. A.; Early, T. R.; Feltell, R. E.; Lewis, E. J.; McMenamin, R. L.; Navarro, E. F.; OBrien, M. A.; OReilly, M.; Reule, M.; Saxty, G.; Seavers, L. C.; Smith, D. M.; Squires, M. S.; Trewartha, G.; Walker, M. T.; Woolford, A. J. Identification of N -(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1 H -pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design J. Med. Chem. 2008, 51, 4986-4999
13. Hughes, A. CDK inhibitors in 3D: problems with the drugs, their development plans or their linkage to disease? Gene Ther. Mol. Biol. 2006, 10, 41-54
14. Yamaoka, K.; Saharinen, P.; Pesu, M.; Holt, V. E. T.; Silvennoinen, O.; OShea, J. J. The Janus kinases (Jaks) Genome Biol. 2004, 5, 253.1-253.6
15. Baxter, E. J.; Scott, L. M.; Campbell, P. J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G. S.; Bench, A. J.; Boyd, E. M.; Curtin, N.; Scott, M. A.; Erber, W. N.; Green, A. R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 2005, 365, 1054-1061
16. James, C.; Ugo, V.; Le Couedic, J. P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garcon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; Villeval, J. L.; Constantinescu, S. N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 2005, 434, 1144-1148
17. Levine, R. L.; Loriaux, M.; Huntly, B. J.; Loh, M. L.; Beran, M.; Stoffregen, E.; Berger, R.; Clark, J. J.; Willis, S. G.; Nguyen, K. T.; Flores, N. J.; Estey, E.; Gattermann, N.; Armstrong, S.; Look, A. T.; Griffin, J. D.; Bernard, O. A.; Heinrich, M. C.; Gilliland, D. G.; Druker, B.; Deininger, M. W. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia Blood 2005, 106, 3377-3379
18. Lin, Q.; Meloni, D.; Pan, Y.; Xia, M.; Rodgers, J.; Shepard, S.; Li, M.; Galya, L.; Metcalf, B.; Yue, T. Y.; Liu, P.; Zhou, J. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction Org. Lett. 2009, 11, 1999-2002
19. William, A. D.; Lee, A. C.; Blanchard, S.; Poulsen, A.; Teo, E. L.; Nagaraj, H.; Tan, E.; Chen, D.; Williams, M.; Sun, E. T.; Goh, K. C.; Ong, W. C.; Goh, S. K.; Hart, S.; Jayaraman, R.; Pasha, M. K.; Ethirajulu, K.; Wood, J. M.; Dymock, B. W. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5,7,26-triaza-tetracyclo[19.3.1. 1(2,6).1(8,12)]heptacosa-1(25),2(26), 3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma J. Med. Chem. 2011, 54, 4638-4658
20. Verstovsek, S.; Deeg, H. J.; Odenike, O.; Zhu, J.; Kantarjian, H. M.; Estrov, Z.; Scott, B. L.; Thomas, D. A. Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis Blood 2010, 116, Abstract 3082
21. Verstovsek, S.; Kantarjian, H.; Mesa, R. A.; Pardanani, A. D.; Cortes-Franco, J.; Thomas, D. A.; Estrov, Z.; Fridman, J. S.; Bradley, E. C.; Erickson-Viitanen, S.; Vaddi, K.; Levy, R.; Tefferi, A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N. Engl. J. Med. 2010, 363, 1117-1127
22. Verstovsek, S.; Odenike, O.; Scott, B.; Estrov, Z.; Cortes, J.; Thomas, D.; Wood, J.; Ethirajulu, K.; Lowe, A.; Zhu, H. J.; Kantarjian, H.; Deeg, H. J. Phase I dose escalation trial of SB1518, a novel JAK2-FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-ET/post-PV myelofibrosis Blood 2009, 114, Abstract 3905
23. Kindler, T.; Lipka, D. B.; Fischer, T. FLT3 as a therapeutic target in AML: still challenging after all these years Blood 2010, 116, 5089-5102
24. Gilliland, D. G. FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors Best Prac. Res., Clin. Haematol. 2003, 16, 409-417
25. Quentmeier, H.; Reinhardt, J.; Zaborski, M.; Drexler, H. G. FLT3 mutations in acute myeloid leukemia cell lines Leukemia 2003, 17, 120-124
26. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J. Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3 Z)-ylidenemethyl]-2,4-dimethyl-1 H -pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J. Med. Chem. 2003, 46, 1116-1119
27. Bankston, D.; Dumas, J.; Natero, R.; Riedl, B.; Monahan, M.-K.; Sibley, R. A scaleable synthesis of BAY 43-9006: a potent raf kinase inhibitor for the treatment of cancer Org. Process Res. Dev. 2002, 6, 777-781
28. William, A. D.; Lee, A.; Blanchard, S.; Poulsen, A.; Teo, E.; Nagaraj, H.; Tan, E.; Chen, D.; Williams, M.; Sun, E.; Goh, K. C.; Ong, W.; Goh, S. K.; Hart, S.; Jayaraman, R.; Pasha, M. K.; Ethirajulu, K.; Wood, J.; Dymock, B. W. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26- triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27), 16,21,23-decaene (SB1518), a potent Janus kinase 2/Fms-liketyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma J. Med. Chem. 2011, 54, 4638-4658
29. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery-an underexploited structural class Nat. Rev. Drug Discovery 2008, 7, 608-624
30. Marsault, E.; Peterson, M. L. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery J. Med. Chem. 2011, 54, 1961-2004
31. Schmidt, B. Ruthenium-catalyzed cyclizations: more than just olefin metathesis! Angew. Chem., Int. Ed. 2003, 42, 4996-4999
32. Cai, Q.; Zhao, Z.-A.; You, S.-L. Asymmetric construction of polycyclic indoles through olefin cross-metathesis/intramolecular Friedel-Crafts alkylation under sequential catalysis Angew. Chem., Int. Ed. 2009, 48, 7428-7431
33. Deiters, A.; Martin, S. F. Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis Chem. Rev. 2004, 104, 2199-2238
34. Kim, S.; Hwang, W.; Lim, I. S.; Kim, S. H.; Lee, S.-G.; Kim, B. M. Acid-mediated activation of modified ring-closing metathesis catalysts Tetrahedron Lett. 2010, 51, 709-713
35. Molecular Modeling Platform; Schrödinger, LLC: New York, NY, 2011; http://www.schrodinger.com.
36. Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A.; Ong, K. H.; Dymock, B. W.; Ethirajulu, K.; Burrows, F.; Wood, J. M. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia [Online early access]. DOI: 10.1038/leu.2011.218. Published Online: Aug 23, 2011.
37. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and yesting of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236
38. Hasel, W.; Hendrickson, T. F.; Still, W. C. A rapid approximation to the solvent accessible surface areas of atoms Tetrahedron Comput. Methodol. 1988, 1, 103-116
39. Lawrie, A. M.; Noble, M. E.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 Nat. Struct. Biol. 1997, 4, 796-801
40. Griffith, J.; Black, J.; Faerman, C.; Swenson, L.; Wynn, M.; Lu, F.; Lippke, J.; Saxena, K. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Mol. Cell 2004, 13, 169-178
41. Protein Data Bank. www.pdb.org.